Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease

Documenti analoghi

• Almost Half of the Dupilumab‐Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year
  di: Josje J. Otten, et al.
  Pubblicazione: (2025)
• “Super‐Responders” to Dupilumab Treatment in Patients With Primary Diffuse Chronic Rhinosinusitis With Nasal Polyps
  di: P. E. Vonk, et al.
  Pubblicazione: (2025)
• Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage
  di: Eugenio De Corso, et al.
  Pubblicazione: (2025)
• Trends in Dupilumab Utilization for the Treatment of Chronic Rhinosinusitis With Nasal Polyps
  di: Daniel Xiao, et al.
  Pubblicazione: (2024)
• Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis
  di: W. J. Fokkens, et al.
  Pubblicazione: (2024)